JAGX PE Ratio & Valuation,Is JAGX Overvalued

JAGX Relative Valuation

JAGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JAGX is overvalued; if below, it's undervalued.

Historical Valuation

Jaguar Health Inc (JAGX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.33 is considered Fairly compared with the five-year average of -2.16. The fair price of Jaguar Health Inc (JAGX) is between 0.96 to 2.14 according to relative valuation methord.

Relative Value

Fair Zone

0.96-2.14

Current Price：1.23

Fair

-0.15

-9.21

EV/EBITDA

Jaguar Health Inc. (JAGX) has a current EV/EBITDA of -9.21. The 5-year average EV/EBITDA is 2.68. The thresholds are as follows: Strongly Undervalued below -25.45, Undervalued between -25.45 and -11.38, Fairly Valued between 16.75 and -11.38, Overvalued between 16.75 and 30.81, and Strongly Overvalued above 30.81. The current Forward EV/EBITDA of -9.21 falls within the Historic Trend Line -Fairly Valued range.

-1.46

EV/EBIT

Jaguar Health Inc. (JAGX) has a current EV/EBIT of -1.46. The 5-year average EV/EBIT is -2.48. The thresholds are as follows: Strongly Undervalued below -7.47, Undervalued between -7.47 and -4.97, Fairly Valued between 0.02 and -4.97, Overvalued between 0.02 and 2.52, and Strongly Overvalued above 2.52. The current Forward EV/EBIT of -1.46 falls within the Historic Trend Line -Fairly Valued range.

0.33

Jaguar Health Inc. (JAGX) has a current PS of 0.33. The 5-year average PS is 3.49. The thresholds are as follows: Strongly Undervalued below -9.01, Undervalued between -9.01 and -2.76, Fairly Valued between 9.74 and -2.76, Overvalued between 9.74 and 15.98, and Strongly Overvalued above 15.98. The current Forward PS of 0.33 falls within the Historic Trend Line -Fairly Valued range.

-0.39

P/OCF

Jaguar Health Inc. (JAGX) has a current P/OCF of -0.39. The 5-year average P/OCF is -1.65. The thresholds are as follows: Strongly Undervalued below -6.41, Undervalued between -6.41 and -4.03, Fairly Valued between 0.74 and -4.03, Overvalued between 0.74 and 3.12, and Strongly Overvalued above 3.12. The current Forward P/OCF of -0.39 falls within the Historic Trend Line -Fairly Valued range.

-1.19

P/FCF

Jaguar Health Inc. (JAGX) has a current P/FCF of -1.19. The 5-year average P/FCF is 3.90. The thresholds are as follows: Strongly Undervalued below -31.33, Undervalued between -31.33 and -13.71, Fairly Valued between 21.51 and -13.71, Overvalued between 21.51 and 39.12, and Strongly Overvalued above 39.12. The current Forward P/FCF of -1.19 falls within the Historic Trend Line -Fairly Valued range.

Jaguar Health Inc (JAGX) has a current Price-to-Book (P/B) ratio of 1.58. Compared to its 3-year average P/B ratio of 0.84 , the current P/B ratio is approximately 89.23% higher. Relative to its 5-year average P/B ratio of 3.18, the current P/B ratio is about -50.26% higher. Jaguar Health Inc (JAGX) has a Forward Free Cash Flow (FCF) yield of approximately -471.48%. Compared to its 3-year average FCF yield of -437.59%, the current FCF yield is approximately 7.74% lower. Relative to its 5-year average FCF yield of -291.95% , the current FCF yield is about 61.50% lower.

1.58

P/B

Median3y

0.84

Median5y

3.18

-471.48

FCF Yield

Median3y

-437.59

Median5y

-291.95

Competitors Valuation Multiple

The average P/S ratio for JAGX's competitors is 0.39, providing a benchmark for relative valuation. Jaguar Health Inc Corp (JAGX) exhibits a P/S ratio of 0.33, which is -16.56% above the industry average. Given its robust revenue growth of -0.80%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of JAGX decreased by 94.65% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 3.11M to 3.08M.

The secondary factor is the Margin Expansion, contributed -2.94%to the performance.

Overall, the performance of JAGX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

-0.80%

3.11M → 3.08M

Revenue Growth

-2.94%

-322.43 → -312.94

Margin Expansion

-90.91%

-0.43 → -0.04

P/E Change

-94.65%

25.25 → 1.35

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Jaguar Health Inc (JAGX) currently overvalued or undervalued?

What is Jaguar Health Inc (JAGX) fair value?

JAGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Jaguar Health Inc (JAGX) is between 0.96 to 2.14 according to relative valuation methord.

How does JAGX's valuation metrics compare to the industry average?

What is the current P/B ratio for Jaguar Health Inc (JAGX) as of Dec 15 2025?

As of Dec 15 2025, Jaguar Health Inc (JAGX) has a P/B ratio of 1.58. This indicates that the market values JAGX at 1.58 times its book value.

What is the current FCF Yield for Jaguar Health Inc (JAGX) as of Dec 15 2025?

As of Dec 15 2025, Jaguar Health Inc (JAGX) has a FCF Yield of -471.48%. This means that for every dollar of Jaguar Health Inc’s market capitalization, the company generates -471.48 cents in free cash flow.

What is the current Forward P/E ratio for Jaguar Health Inc (JAGX) as of Dec 15 2025?

As of Dec 15 2025, Jaguar Health Inc (JAGX) has a Forward P/E ratio of -0.15. This means the market is willing to pay $-0.15 for every dollar of Jaguar Health Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Jaguar Health Inc (JAGX) as of Dec 15 2025?

As of Dec 15 2025, Jaguar Health Inc (JAGX) has a Forward P/S ratio of 0.33. This means the market is valuing JAGX at $0.33 for every dollar of expected revenue over the next 12 months.

JAGX Valuation